title: Livedo racemosa, secondary to drug-induced systemic lupus erythematosus.
abstract: We present a 40-year-old man with erythematous-to-violaceous, broken, reticulated patches on the upper chest, back, and extremities, which is consistent with livedo racemosa. The cutaneous findings appeared after an increase in dilantin dose and subsequently improved after a reduction in dilantin dose. Furthermore, antinuclear antibodies and antihistone antibodies were detected. We therefore believe that the livedo racemosa is a cutaneous manifestation of a drug-induced systemic lupus erythematosus. We review the distinctive features of livedo racemosa as well as its associations with several disorders. Although there are no effective treatments for livedo racemosa, patients often are placed on low-dose aspirin and counseled to avoid smoking in an effort to protect against their increased risk of stroke and arterial thrombosis.
authors.affiliation: Department of Dermatology, New York University, New York, NY, USA.
authors.forename: Taylor
authors.initials: T
authors.lastname: Defelice
authors.forename: Phoebe
authors.initials: P
authors.lastname: Lu
authors.forename: Aaron
authors.initials: A
authors.lastname: Loyd
authors.forename: Rishi
authors.initials: R
authors.lastname: Patel
authors.forename: Andrew G
authors.initials: AG
authors.lastname: Franks
mesh_terms: D000328:Adult; D001241:Aspirin / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood; D006657:Histones / Q000097:blood / Q000276:immunology; D006801:Humans; D054068:Livedo Reticularis / Q000175:diagnosis; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced* / Q000150:complications; D008297:Male; D010672:Phenytoin / Q000009:adverse effects* / Q000627:therapeutic use; D017445:Skin Diseases, Vascular / Q000175:diagnosis* / Q000209:etiology*; D012907:Smoking / Q000009:adverse effects
chemical_list: D001323:Autoantibodies; D006657:Histones; D010672:Phenytoin; D001241:Aspirin